Article
[Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population(PROFILE-F Study)].
Gan to kagaku ryoho. Cancer & chemotherapy - 1 Nov 2019
Kumaki Yuichi, Takahashi Kenta, Mitsumura Takahiro, Yokobori Junko, Takamine Eriko, Ishibashi Eri, Sakashita Hiroyuki, Ishikawa Toshiaki, Ono Hiroaki, Ban Daisuke, Kudo Atsushi, Oshima Noriko, Nakagawa Tsuyoshi, Kimura Koichiro, Kubota Kazunori, Onishi Iichiro, Tanabe Minoru, Uetake Hiroyuki, Miyake Satoshi, Ikeda Sadakatsu
Abstract excerpt
BACKGROUND: FoundationOne CDx is a cancer genome profiling test that has already been approved by the FDA, but its clinical utility in Japanese patients is unknown. In this study, we examined the clinical utility of FoundationOne CDx. METHODS: 46 samples from 43 Japanese pretreated patients with advanced solid tumors were tested with FoundationOne CDx between September 2018-January 2019. RESULTS: The median age...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.